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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the aetiological agent of Kaposi’s sarcoma (KS), the most frequently arising
malignancy in individuals with untreated HIV/AIDS. There are several lines of evidence to indicate that Kaposi’s sarcoma
oncogenesis is associated with loss of T-cell-mediated control of KSHV-infected cells. KSHV can establish life-long asymptomatic
infection in immune-competent individuals. However, when T-cell immune control declines, for example, through AIDS or
treatment with immunosuppressive drugs, both the prevalence of KSHV infection and the incidence of KS in KSHV carriers
dramatically increase. Moreover, a dramatic and spontaneous improvement in KS is frequently seen when immunity is restored,
for example, through antiretroviral therapy or the cessation of iatrogenic drugs. In this paper we describe the current state of
knowledge on the T-cell immune responses against KSHV.
1.Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) (or human
herpesvirus 8 (HHV8)) is an oncogenic herpesvirus that is
the aetiological agent of Kaposi’s sarcoma (KS), a mesenchy-
mal tumour that is the most frequently arising cancer in
individuals with untreated HIV/AIDs [1] and consequently
one of the most common cancers in Sub-Saharan Africa [2].
KSHV is also involved in the pathogenesis of at least two
lymphoproliferative disorders—primary eﬀusion lymphoma
(PEL) and multicentric Castleman’s disease (MCD).
In immunocompetent hosts, KSHV can establish per-
sistent, asymptomatic infection. KSHV infection has been
reported in 3 to 20 percent of US blood donors [3, 4]a n d4 0
to 80 percent of the general population of East African coun-
tries [3, 5, 6]. However, upon immunosuppression (acquired
or iatrogenic) both the seroprevalence of KSHV and the
incidence of KS in KSHV carriers signiﬁcantly increase. KS is
more than 100 times more common in immunosuppressed
individuals, such as HIV-infected individuals and transplant
recipients, compared to immunocompetent individuals [1].
Individuals acquiring KSHV infection with preexisting HIV
infection have a signiﬁcantly higher risk of developing KS;
almost 50% develop KS, indicating that in this setting KSHV
is one of the most oncogenic human viruses known [7].
This indicates that loss of T-cell-mediated immune control
allows KSHV-infected cells to proliferate unchecked and
KSHV-related tumours to develop. Furthermore, a dramatic
clinical improvement is seen in iatrogenic KS patients when
general immunity is restored following the withdrawal of
immunosuppressive drugs [8], and spontaneous tumour
regression has been reported in individuals with AIDS-
related KS (AIDS-KS) after starting anti-HIV therapy [9].
Recent evidence indicates that a positive clinical outcome is
associated with the restoration of KSHV-speciﬁc immunity
[10, 11]. Thus, successful immunity targeted against KSHV
plays a key role in containing KSHV infection, enabling the
virus to establish controlled life-long infection and to coexist
with its host.
However, the relationship between the immune system
and KS oncogenesis is extremely complex. An unusual
feature of KS tumour biology is the important role played by2 Advances in Virology
inﬂammatoryinﬁltrates,particularlyatKSonset.Inﬁltration
of the tumour site by peripheral blood mononuclear cells
(PBMCs) that secrete high levels of Th1 cytokines precedes
the formation of spindle (tumour) cells and appears to be
essential to tumour formation [12]. Most KS lesions are
polyclonal,andmultiplelesionsfromthesameindividualare
also mainly polyclonal [13, 14]. The accepted interpretation
of these data is that KS starts as a hyperplastic polyclonal
lesion that is associated with inﬂammation and KSHV
infection that could give rise, under speciﬁc circumstances,
to clonal metastatic lesions. This supports the idea that
KS is only truly neoplastic in advanced stages [15]. KS
thus exempliﬁes an inﬂammatory-driven oncogenic pro-
cess, or paracrine neoplasia [16]. The development of KS
m a yt h u sb es e e na sam u l t i f a c t o r i a lp r o c e s si nw h i c h :
infection by KSHV is a requirement; immunosuppression
is an important cofactor; and, paradoxically, some level
of systemic and localised immune activation in the form
of increased Th1 cytokine production (induced either by
KSHV infection, HIV infection, or unknown causes) is also
involved.
2.The Targets of the KSHV-Speciﬁc
T-Cell Response
Identifying the targets of the host’s cellular immune
responses is important to our understanding of how KSHV
infections are controlled in immunocompetent individuals
and is a crucial step towards developing treatments such as
immunotherapies, or even vaccines, against KSHV-related
diseases.
T-cell responses to KSHV have been studied mostly in
KS patients and asymptomatic carriers of KSHV. Responses
have been detected against several lytic and latent proteins
[17–28, 31, 34, 38]. Some of these responses have been
demonstrated to be functionally cytotoxic in vitro [17, 18],
and there is some evidence they exert evolutionary pressure
on the virus in vivo [19]. A few HLA-restricted KSHV-
speciﬁc T-cell epitopes have been identiﬁed (see [19–28]
summarised in Table 1). However, these are almost exclu-
sively CD8 epitopes, and they elicit weak T-cell responses
compared to epitopes from other viruses, such as HIV-
1 and Epstein-Barr virus ((EBV), a human γ-herpesvirus
closely related to KSHV) [20, 21]. Neither the breadth
of the antigenic repertoire of the KSHV-speciﬁc T-cell
immuneresponse,noritsimmunodominanttargets,arefully
understood.
Our recent studies indicated that both the CD8 and
CD4T-cellresponsesagainstKSHVpreferentiallytargetearly
and late lytic gene products [31]. This appears to contrast
with what is observed in the CD8 response against EBV,
which is heavily skewed towards EBV genes expressed in the
immediate-early stage of the lytic cycle [32]. However, it is in
keepingwithrecentobservationsintheCD8responseagainst
the murine γ-herpesvirus MHV68 (more closely related to
KSHV than to EBV), which also preferentially targets early
and late lytic gene products [33].
3. The CD8T-Cell Response againstKSHV
3.1. CD8 T-Cell Responses to Primary Infection. Unlike
primary EBV infection, which in adolescents and adults
often results in acute infectious mononucleosis, primary
KSHV infection appears not to be associated with any
speciﬁc severe illness. Studies of cohorts at risk of KSHV
infection have identiﬁed adults and children undergoing
KSHV seroconversion and report occasional mild symptoms
of fatigue, diarrhoea, fever, and localised rash [34, 35]. The
lack of notable symptoms makes identifying primary KSHV
infection a challenge, and thus little is known about the T-
cell response to KSHV at acquisition. A 15-year longitudinal
study of HIV-negative adults at risk of KSHV infection
identiﬁed ﬁve individuals who had seroconverted during
the study period and retrospectively analysed cryopreserved
PBMCs from blood samples taken from these individuals
for several years before and after KSHV seroconversion
[34]. The authors ﬁrst looked for global changes in T-cell
phenotype around the time of KSHV seroconversion, as
expansion of activated CD8 T cells is a classic ﬁnding in
EBV mononucleosis in adults [36, 37]. They observed no
generalised expansion of CD8 or CD4 T-cell populations
after primary KSHV infection, and no changes in the
expression of na¨ ıve and memory markers CD45RA and
CD45RO, or of activation and costimulatory markers CD38,
CD28,andHLA-DR[34].Theauthorsw er e,ho w ev er ,ablet o
detect KSHV-speciﬁc CD8 T-cell responses directed against
a broad spectrum of immediate-early, early, and late lytic
KSHV ORFs. Such responses were observed at the time of
primary KSHV infection in all KSHV seroconverters. The
authors observed no dominant CTL target between the study
subjects [34].
A second study examined two HLA-A2-positive
KSHV-negative recipients of kidneys from KSHV-positive
donors [23]. Both recipients remained consistently clear
of detectable KSHV infection for 24 and 11 months after
transplantation, respectively. Strikingly, CD8 T cells speciﬁc
for both lytic and latent KSHV ORFs were detected in one
of these recipients whose donor was also HLA-A2-positive.
The second recipient, whose donor was HLA-A2-negative,
showed no detectable response. The authors, therefore,
suggest that KSHV-speciﬁc CTLs are restricted by shared
donor/recipient HLA alleles, in this case HLA-A2. In the ﬁrst
recipient, the majority of tetramer-positive CD8 T cells were
of a terminally diﬀerentiated eﬀector memory phenotype
(CD45RA+CCR7−) and expressed perforin, indicating that
the generation of a functional KSHV-speciﬁc CTL response
can lead to abortive infection [23]. In keeping with this,
KSHV-speciﬁc T-cell responses have also been detected in
KSHV-seronegative individuals deﬁned as being at high risk
of KSHV infection [38]. The authors argued that overall
evidence from this study indicated that those individuals
who did not show a detectable KSHV serologic response,
but who showed positive KSHV-speciﬁc T-cell responses,
were indeed KSHV-infected. It is possible, therefore, that
a very low level of viral replication may be suﬃcient to
prime a KSHV-speciﬁc T-cell immune response that may
confer protection against chronic KSHV infection. However,Advances in Virology 3
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it is perhaps more likely that the current serological and
PCR-based methods for detecting KSHV infection are not
sensitive enough to identify low-level latent infection.
3.2. Frequency and Diversity of CD8 T-Cell Responses in
Asymptomatic Infection and Disease. In the study of ﬁve
KSHV seroconverters discussed above, the frequencies of
both CD8 CTL precursors and CD8 IFNγ-producing cells,
directed against lytic KSHV antigens, increased to a peak
one-to-two years after primary infection, after which they
decreased in correlation with declines in antibody titres,
possibly due to decreased viral replication and lower anti-
genic burden [34]. One study reported that T-cell responses
to KSHV increased with viral load in the peripheral blood
and were more readily detectable in individuals with active
KS than those who did not present with active KS [38].
However, other groups have been unable to conﬁrm this,
andthereisotherwisestrongevidence(discussedbelow)that
high levels of KSHV-speciﬁc CD8 T-cell responses confer
protection against KS oncogenesis. Responses to KSHV CD8
peptides have been found to be of higher frequency and
of greater diversity in their antigenic repertoire in asymp-
tomatic carriers of KSHV compared to those with either
AIDS-related, classic, or iatrogenic KS [22, 23, 29]. KSHV-
speciﬁc T-cell responses appeared concurrent with clinical
improvement in iatrogenic KS patients after a reduction
of their immunosuppressive therapy or a conversion from
calcineurin inhibitors (which block calcineurin-activated
transcription of IL2) to sirolimus (also known as rapamycin,
which acts through mTOR to inhibit responses to IL2)
[29]. A longitudinal study of an iatrogenic KS patient who
presented with recurrent episodes of remission and relapse
of KS lesions found a correlation between reduced frequency
of KSHV-speciﬁc CD8 T cells and recurrence of active KS
[23]. Furthermore, both the magnitude and the frequency
of responses to KSHV CD8 peptides increase with immune
reconstitution through HAART, which apparently correlates
with spontaneous KS regression [11, 28].
To address whether low frequencies of KSHV-speciﬁc
CD8 T cells in the peripheral blood of KS patients is due
to recruitment of these cells to the site of the tumour, one
group performed in situ tetramer staining, and confocal
laser scanning microscopy on KS biopsy specimens from two
patients who had detectable circulating KSHV-speciﬁc CD8
T cells at the time of biopsy. They found large numbers
of KSHV-tetramer-negative CD8 T-cell inﬁltrates in the
vicinityofKSHVLANA1-positivespindle(tumour)cells,but
observed very few CD8 T cells that costained with KSHV
tetramers. The few tetramer-positive CD8 inﬁltrates that
were seen were mainly found in LANA1-negative tissue [23].
Thus, in this study, KSHV-tetramer-speciﬁc CD8 T cells did
not appear to be preferentially recruited to inﬂamed tumour
tissue. Further investigation is warranted to conﬁrm these
ﬁndings and to understand their biological relevance.
Together, the above data indicate that KS oncogenesis
is associated with loss of CD8 T cell-mediated control
of KSHV-infected cells. Interestingly, a study investigat-
ing KSHV-speciﬁc CD8 T-cell responses in multicentric
Castleman’s disease (MCD) found that individuals with
MCD had similar frequencies of KSHV-speciﬁc CD8 T-cell
responses, and these were directed against a similar antigenic
repertoire, as compared to asymptomatic KSHV carriers
[30]. Another group also reported high numbers of IFNγ-
secreting KSHV-speciﬁc CD8 T-cells in two individuals with
MCD [39]. This is in direct contrast to what is observed in
KS and indicates that whilst KSHV-speciﬁc CD8 T cells may
confer protection against the emergence of KS, they do not
apparently protect against the development of MCD.
3.3. Functional Properties and Phenotypes of KSHV-Speciﬁc
CD8 T Cells in Asymptomatic Infection and Disease. The
preciseroleofKSHV-speciﬁcCD8Tcellsinthepathogenesis
orcontrolofKSHV-relateddiseasesmayadditionallydepend
on the functional properties and diﬀerentiation phenotypes
ofthesecells.EBV-speciﬁcandHIV-speciﬁcCD8Tcellshave
been shown to produce a range of cytokines besides inter-
feron IFNγ [40], and there is evidence that polyfunctional T-
cell responses may be a correlate of control of HIV-infection
[41]. However, little is known about the functionality of
KSHV-speciﬁc CD8 T cells in asymptomatic infection and
disease. Both monofunctional and polyfunctional responses
to a number of epitopes were reported in HIV-negative
asymptomatic carriers of KSHV [24]. One study compared
cytokine release by CD8 T cells from four individuals with
AIDS-KS that spontaneously regressed after initiation of
HAART(“KSnonprogressors”)withcytokinereleasebyCD8
T cells from three individuals with AIDS-KS that progressed
and required additional chemotherapy, despite initiation of
HAART (“KS progressors”) [42]. It was shown that KSHV-
speciﬁc CTL responses from KS nonprogressors were more
frequently polyfunctional (production of both IFNγ and
TNFα)thanCTLresponsesfromKSprogressors.Incontrast,
KSHV-speciﬁc CD8 T cells from both individuals with MCD
and asymptomatic carriers of KSHV were demonstrated to
be polyfunctional (secretion of two or more of IFNγ,I L 2 ,
TNFα, MIP1ß, or mobilisation of CD107a) after stimulation
with pools of both lytic and latent peptides [30]. A study
comparing the functionality of KSHV-speciﬁc CD8 T cells
directed against lytic or latent antigens in HIV-positive
asymptomatic carriers of KSHV found that multifunctional
KSHV-speciﬁc T cells that responded to latent antigens were
more frequently detected in CD8 T-cell populations than
those targeted to lytic antigens, in keeping with observations
in EBV-speciﬁc T cells [20].
Human memory CD8 and CD4 T cells can be divided
into phenotypic subsets based on their functions and expres-
sionofcertaincellsurfacemarkers.Thesesubsetsarebroadly
deﬁned as central memory (TCM), eﬀector memory (TEM),
and terminally diﬀerentiated eﬀector memory (TEMRA:a
subset of CD8 T cells only) [43]. Eﬀector memory T cells
can be further subdivided into early-, intermediate-, and
late-eﬀector memory cells [44]. TCM cells have little or no
eﬀector function but migrate to lymph nodes and readily
proliferate and diﬀerentiate into TEM cells in response to
stimulation by their speciﬁc antigen [45]. TEM cells migrate
to inﬂamed tissues and are characterised by rapid eﬀector6 Advances in Virology
function upon antigenic stimulation. Early and intermediate
TEM cells have low cytolytic activity and maintain high
proliferative capacity. Late TEM c e l l sh a v el e s sp r o l i f e r a t i v e
capacity but strong eﬀector cytolytic function [44, 46].
TEMRA cells are a unique subclass of CD8 TEM cells that are
fully diﬀerentiated, strongly cytolytic, carry large amounts
of perforin, and are nonreplicative. They are a hallmark of a
p r o l o n g e di m m u n er e s p o n s e[ 43]. The expression of several
cell-surfacemolecules can be used to deﬁne memory subsets.
In a study of three iatrogenic KS patients, conversion
of their immunosuppressive drug regime from calcineurin
inhibitors to sirolimus (also known as rapamycin, as
described above) led to an increase in the frequency of na¨ ıve
and central memory T cells in the general population of cir-
culating CD8 T cells in conjunction with KS regression [29].
A recent study found, unexpectedly, that treating mice with
rapamycin (previously classiﬁed as an immunosuppressive
drug, as it inhibits responses to IL2) following infection with
lymphocytic choriomeningitis virus (LCMV) enhanced both
the quality and quantity of central memory virus-speciﬁc T
cells [47]. Thus, converting these iatrogenic KS patients to
sirolimus may be acting to promote an enrichment of their
central memory CD8 T cell pool, and these cells may be
playing an important role in keeping KSHV-infected cells in
check and promoting regression of KS lesions.
There are few studies of the diﬀerentiation phenotype
of KSHV-speciﬁc CD8 T cells. The few reports to date are
somewhat contradictory and on the whole rather limited,
particularly in terms of sample numbers. This, coupled with
the complication of the background of immunosuppression
(acquired or iatrogenic) in which the studies are conducted,
means that a deﬁnitive understanding of the diﬀerentiation
phenotype of KSHV-speciﬁc T cells remains elusive.
Six transplant recipients who spontaneously controlled
KSHV infection had signiﬁcantly higher proportions of
CD45RA+CCR7− TEMRA KSHV-speciﬁc cells and signiﬁ-
cantly lower proportions of CD45RA−CCR7− TEM KSHV-
speciﬁc cells, compared to seven patients with active
KS and ﬁve patients with KS in remission [23]. In six
MCD patients, the majority of KSHV-speciﬁc CD8 T cells
were also CD45RA−CCR7− TEM cells. However, in this
study, the dominance of this phenotype did not diﬀer
from that of seven HIV-positive asymptomatic carriers of
KSHV. Furthermore, in the MCD patients, a signiﬁcantly
higher proportion of KSHV-speciﬁc CD8 T cells were
found to be CD45RA−CCR7−CD27− late eﬀector mem-
ory T cells and a correspondingly lower proportion were
CD45RA−CCR7−CD27+ early and intermediate eﬀector
memory T cells, as compared to asymptomatic carriers
[30]. This more diﬀerentiated phenotype correlated with
increased viral load, and was postulated to result from high
antigenic burden.
Two studies have compared the phenotypes of KSHV-
speciﬁc T cells targeting either lytic or latent antigens.
One group reportedly observed no diﬀerence between the
diﬀerentiation phenotype of KSHV-speciﬁc CD8 T cells
targeted against latent or lytic antigens [23]. However,
it was not made clear whether or not they compared T
cells speciﬁc for diﬀerent antigens from within the same
individual, or if they only compared lytic-antigen-speciﬁc
T cells from one individual with latent-antigen-speciﬁc
T cells from another individual. Neither was it clear how
many responses were investigated, nor in how many
individuals. Another group reported that CD8 T cells that
recognised latent KSHV antigens were predominately of a
CD45RA−CCR7− TEM phenotype, with a low proportion
of cells of a CD45RA+CCR7− TEMRA phenotype whereas a
much higher proportion of CD8 T cells directed against lytic
KSHV antigens were CD45RA+CCR7− TEMRA [20]. This
is in keeping with observations of the memory phenotypes
of EBV-speciﬁc T cells [48]. Interestingly, KSHV-speciﬁc T
cells were overall more diﬀerentiated (higher proportions of
CD45RA+CCR7− cells) than EBV-speciﬁc T cells [20].
4. The CD4T-Cell Response againstKSHV
The CD4 T-cell response against KSHV remains largely
unexplored. Although some studies have looked at responses
to KSHV by mixed CD8 and CD4 T-cell populations [10, 20,
38], there have been very few investigations speciﬁcally into
the CD4 T-cell response against KSHV. One of the studies
with mixed T cells reported that two samples out of 11 tested
showed borderline CD4 T-cell reactivity [20]. They did not
state which of the two antigens they were testing (ORF57
(lytic) and ORF73 (latent)) initiated these CD4 responses.
Another group reported the identiﬁcation of two CD4 T-cell
epitopes (the only ones described to date) from within the
latent antigens K12 and K15 in one individual with AIDS-KS
[22]. In a few individuals, our group was able to detect CD4
responses to monocyte-derived dendritic cells lentivirally
transduced to express KSHV antigens [31]. These were
less frequently detected than CD8 responses but appeared
to preferentially target early and late lytic antigens. The
longitudinal study of three iatrogenic KS patients described
in the CD8 response section above reported the emergence
of CD4 responses to K12 (latent) and K8.1 (late lytic),
in conjunction with KS regression in two of these three
individuals [29]. The single individual in whom no KSHV-
speciﬁc CD4 responses were observed was the only one out
of the three that did not achieve full remission of their
KS. The authors suggested that this was indicative of the
importance of KSHV-speciﬁc CD4 responses in controlling
KSHV infection. Although the small sample number and
limited number of antigens make it diﬃcult to reach a ﬁrm
conclusion from this study, it seems likely that CD4 T cells
may play a key role in the immune response against KSHV.
The ﬁnal phases of KSHV virion assembly occur in the
endosomal cellular compartments with extensive targeting
of viral proteins to endosomes. Thus, viral proteins can
be eﬃciently processed through the intracellular endosome
pathway, resulting in the presentation of CD4-speciﬁc viral
epitopes through MHC-II to helper T cells. Processing of the
EBVantigenEBNA1forpresentationinthecontextofMHC-
II is also known to occur through the autophagy pathway
[49]. Furthermore, the presentation of the EBV antigens
EBNA2, EBNA3C and BHRF1 through MHC-II occurs by
intercellular transfer of an antigenic moiety [50–52]. ThisAdvances in Virology 7
process does not require cell contact, and the antigenic
particle is taken up by neighbouring cells and processed
as exogenous antigen for MHC-II-mediated presentation.
It seems reasonable that one or all of these pathways may
also be used for the presentation of KSHV antigens through
MHC-II.
The lack of known CD4 epitopes or antigens has limited
studies into the association between KSHV-speciﬁc CD4
responses and the control of KSHV or the development (and
subsequent resolution) of KSHV-related neoplasms. Low
CD4 counts in persons infected with HIV are associated with
the incidence of KS, and KS can spontaneously regress with
immune reconstitution through HAART. A weak association
was reported between increased CD4 counts after start-
ing HAART and reconstitution of KSHV-speciﬁc immune
responses [10]. Interestingly, however, clinical improvement
of KS after initiation of HAART was not found to be
associated with increased CD4 count, although it was
signiﬁcantly related to decreased HIV viral load [53].
The absence of known targets of the KSHV-speciﬁc
CD4 response has also restricted the investigation of the
functionality (Th1 versus Th2) and the diﬀerentiation phe-
notypes of KSHV-speciﬁc CD4 T cells in chronic infection
and disease. In the three iatrogenic KS patients mentioned
above, complete KS regression in two of the patients was
associated with an expansion of the na¨ ıve and central
memory compartments of the total circulating CD4 T-
cell population. In the third patient, who did not achieve
complete resolution of their KS, there was no enrichment of
their central memory CD4 T-cell compartment, consistent
with these cells playing a role in KS control.
5. γδ T Cells in the Control of KSHV
CD4 and CD8 T cells make up the majority of CD3 T
cells found in the body and are both characterised by T-cell
receptors comprised of an α-chain and a β-chain. A small
proportion of CD3 T cells have T-cell receptors made up of a
γ-chain and a δ-chain and are thus known as γδ T cells. γδ T
cells typically account for less than ﬁve percent of circulating
T cells, but are enriched in epithelial-rich tissues such as the
skin and intestines [54] .T h e r ea r et w om a i ns u b t y p e so fγδ
T cells, designated Vδ1a n dV δ2. In certain disease states,
the representation of Vδ1a n dV δ2 shifts dramatically, for
example in HIV-1 infection, Vδ2 cells are lost and Vδ1c e l l s
expand [55, 56]. Although the signiﬁcance of such changes is
not understood, they imply a role for γδ T cells in antiviral
immune responses [54].
One group has examined the involvement of γδ Tc e l l si n
the control of chronic KSHV infection [57]. They observed
a signiﬁcant expansion of γδ T cells of the Vδ1s u b t y p ei n
the peripheral blood of HIV-negative asymptomatic carriers
of KSHV, as compared to age-matched, HIV-negative, and
KSHV-negative healthy controls. Vδ1 T-cell expansion has
been previously described in two instances: in all stages of
HIV infection [55, 56] and in transplant recipients with
active CMV infection [58]. Asymptomatic KSHV infection
is, therefore, the second viral infection (after HIV) in
which speciﬁc, long-lasting Vδ1 T-cell expansion is observed
during chronic stages of infection, and the only viral
infection in which Vδ1 expansion has been documented in
immunocompetent individuals. Barcy and colleagues [57]
further found that in asymptomatic carriers of KSHV, the
γδ Vδ1 T-cell subpopulation displayed an increase in the
relative frequency of cells expressing an eﬀector phenotype
compared to KSHV-negative controls. In vitro experiments
demonstrated Vδ1 T-cell activation in response to infectious
KSHV particles; KSHV-infected cell lines; and the KSHV
viral proteins glycoprotein B (encoded by ORF8), K8.1 and
ORF65 [57]. Moreover, Vδ1 T cells prevented the release
of infectious KSHV virions from KSHV-infected cell lines
following the induction of lytic replication [57].
6.FuturePerspective
There is still much to learn about the adaptive T-cell
responses against KSHV, and the evidence examined above
highlights the diﬃculty in detecting these weak responses as
a major obstacle in the ﬁeld, both in the work completed
to date and for future investigations. Although some CD8
epitopes have been identiﬁed, it seems reasonable that there
may be immunodominant epitopes yet to be determined. It
isevidentthatthetargetsoftheKSHV-speciﬁcCD4response
remain poorly understood. Further characterisation of the
functionality and diﬀerentiation phenotypes of both CD8
and CD4 KSHV-speciﬁc T cells will be greatly aided by
ﬁrst achieving a better understanding of the targets of these
cells. Such future investigations may assist the design of
targetedtherapeuticstrategiestorestoreKSHV-speciﬁcTcell
function, thus controlling KSHV infection in both AIDS and
transplant recipients.
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